Results 211 to 220 of about 109,169 (264)
Some of the next articles are maybe not open access.
European Journal of Clinical Investigation, 1994
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire +2 more sources
Abstract.The evidence in support of the safety and efficacy of aspirin in the secondary prevention of platelet dependent vascular occlusion is compelling. The utility of this drug has stalled the development of potential competitors, such as thromboxane antagonists.
G A, Fitzgerald, E A, Meagher
openaire +2 more sources
Medical Journal of Australia, 1999
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is ...
R I, Baker, G J, Hankey
openaire +3 more sources
Hematology, 2009
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
Abstract The introduction of aspirin as an anti-thrombotic agent some 50 years ago has changed the therapeutic approach in cardiovascular medicine. Since platelets play a key role in the development of arterial thrombosis, antiplatelet drugs serve as a cornerstone in the prevention and the treatment of these conditions.
David, Varon, Galia, Spectre
openaire +2 more sources
The American Journal of Medicine, 1996
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
The major clinical indication for antiplatelet therapy has been the prevention of arterial thrombosis. Arterial thrombi are composed of predominantly platelets formed under conditions of elevated shear stress at sites of atherosclerotic vascular injury and disturbed blood flow.
openaire +2 more sources
Hospital Medicine, 2000
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Within the last few years antiplatelet therapy has developed exponentially, with new agents being tested in an increasing number of clinical scenarios. The mechanism of action of these newer agents and evidence of benefit is prevented in this review.
openaire +2 more sources
Highlights: Introduction Goals of Treatment Antiplatelet Therapy Combination Therapy Monographs ...
Megan Willson, Kimberly C. McKeirnan
openaire +2 more sources
Megan Willson, Kimberly C. McKeirnan
openaire +2 more sources
Antiplatelet therapy in children
Thrombosis Research, 2006Platelets are essential for the maintenance of vascular integrity and control of bleeding at sites of injury, but they are also implicated in the progression of atherosclerotic lesions and arterial vascular thrombosis. The use of antiplatelet drugs for the primary and secondary prevention of cardiovascular and cerebrovascular thromboses in adult ...
Israels, Sara J., Michelson, Alan D.
openaire +3 more sources
Pharmacogenetics of Antiplatelet Therapy
Current Atherosclerosis Reports, 2014There has been substantial progress toward understanding and investigating the specific genetic factors that influence interindividual variations in platelet-directed therapy. There has also been substantial progress toward better understanding of the pharmacogenetics of drug metabolism and phamacodynamic response to platelet antagonists.
Patrick L, Daly, Richard C, Becker
openaire +2 more sources
Antiplatelet drug nonresponsiveness
American Heart Journal, 2008The response to most medication, including antiplatelet drugs, is highly variable between individuals. Observational studies have shown that nonresponders to antiplatelet agents appear to have an increased incidence of vascular events. This review article reviews the background, mechanisms, and evidence in support of the clinical significance of this ...
Patrick, Gladding +4 more
openaire +2 more sources
Australian and New Zealand Journal of Medicine, 1998
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources
AbstractAspirin is an established therapy for the management of acute myocardial infarction (AMI) and unstable angina. Secondary prevention with chronic aspirin therapy is also indicated for patients with stable angina.Aspirin inhibits cyclo‐oxygenase‐I, a key enzyme in the biosynthetic pathway leading to the production of thromboxane A2.
H D, White, J K, French, C J, Ellis
openaire +2 more sources